1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Drugs In Development, 2022, provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Acute lymphocytic leukemia (ALL) is the cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. It enters the blood stream and rapidly progress to other parts of the body such as spleen, lymph nodes and liver. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain and breathing problems. Treatment includes chemotherapy, transfusions, transplant and medications.c
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 7, 100, 114, 15, 10, 119, 17 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages comprises 2, 46, 40, 2, 30, 1 and 1 molecules, respectively.
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview
- Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development
- Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Drug Profiles
- Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects
- Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products
- Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects, 2022
- Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products, 2022
- Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Abclon Inc
- Achelois Cell Therapy
- Actinium Pharmaceuticals Inc
- Actinobac Biomed Inc
- ADC Therapeutics SA
- Adienne Pharma & Biotech SA
- Adlai Nortye Biopharma Co Ltd
- Agastiya Biotech LLC
- AIkido Pharma Inc
- Aileron Therapeutics Inc
- AIMM Therapeutics BV (Inactive)
- Alaunos Therapeutics Inc
- Allterum Therapeutics LLC
- Amgen Inc
- Angiocrine Bioscience Inc
- Apexian Pharmaceuticals Inc
- Arch Oncology Inc
- Armaceutica Inc
- Ascentage Pharma Group International
- Ascentawits Pharmaceuticals Ltd
- AstraZeneca Plc
- Athenex Inc
- Autolus Therapeutics Plc
- Avalon GloboCare Corp
- AvenCell Europe GmbH
- AVM Biotechnology LLC
- Ayala Pharmaceuticals Inc
- Bayer AG
- Beijing Immunochina Pharmaceuticals Co Ltd
- Bellicum Pharmaceuticals Inc
- Bio-Cancer Treatment International Ltd
- Bio-Path Holdings Inc
- Bioceltech Therapeutics Ltd
- Biocure Technology Inc
- Biohaven Pharmaceutical Holding Company Ltd
- Biomea Fusion Inc
- BlueSphere Bio Inc
- Bristol-Myers Squibb Co
- Calithera Biosciences Inc
- Cambridge Innovation Technologies Consulting Ltd
- Caribou Biosciences Inc
- CARsgen Therapeutics Ltd
- Cellectis SA
- Cellestia Biotech AG
- Cellular Biomedicine Group Inc
- Celularity Inc
- Centrymed Pharmaceutical Inc
- Century Therapeutics Inc
- Ceptur Therapeutics Inc
- Changzhou Qianhong Bio-Pharma Co Ltd
- Cheetah Cell Therapeutics Co Ltd
- Chengdu USino Technology Biology Co Ltd
- Chengdu Zenitar Biomedical Technology Co Ltd
- Chimagen Biosciences Ltd
- Chimeric Therapeutics Ltd
- Chimerix Inc
- China Immunotech (Beijing) Biotechnology Co Ltd
- China Immunotech Co Ltd
- Chongqing Precision Biotech Co Ltd
- CoImmune Inc
- ConverGene LLC
- CRISPR Therapeutics AG
- CSPC Pharmaceutical Group Ltd
- Cullinan Oncology Inc
- Curon Biopharmaceutical Ltd
- Cyclacel Pharmaceuticals Inc
- Daiichi Sankyo Co Ltd
- DEKK-TEC Inc
- Delta-Fly Pharma Inc
- DevaCell Inc
- Diatheva srl
- Diazon Pharmaceuticals Inc
- DiNonA Inc
- EdiGene Inc
- Elf Zone Inc
- Enzyme by Design Inc
- Epizyme Inc
- ERYTECH Pharma SA
- Eureka Therapeutics Inc
- Eutilex Co Ltd
- ExCellThera Inc
- Excelmab Inc
- F. Hoffmann-La Roche Ltd
- Fate Therapeutics Inc
- Felicitex Therapeutics Inc
- Fochon Pharmaceutical Ltd
- Fusion Pharmaceuticals US Inc
- Gamida Cell Ltd
- Generium
- Gilead Sciences Inc
- Gracell Biotechnologies Inc
- Guangzhou Bio-gene Technology Co Ltd
- Hangzhou Minsheng Pharmaceutical Group Co Ltd
- Hangzhou Qihan Biotechnology Co Ltd
- Hebei Senlang Biotechnology Co Ltd
- HemoGenyx Pharmaceuticals Plc
- Henan Honghui Biotechnology Co Ltd
- HighPass Bio Inc
- Hillstream BioPharma Inc
- HK inno.N Corp
- Housey Pharmaceutical Research Laboratories LLC
- HRAIN Biotechnology Co Ltd
- Humanigen Inc
- Hunan Siweikang Therapeutics Ltd
- iCell Gene Therapeutics LLC
- iDD biotech SAS
- IGM Biosciences Inc
- Iksuda Therapeutics Ltd
- ImCheck Therapeutics SAS
- ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
- ImmunityBio Inc
- ImmunoAct Pvt Ltd
- ImmunoGen Inc
- Immunotech Biopharm Ltd
- IN8bio Inc
- Inatherys
- Incyte Corp
- Innate Pharma SA
- InnoBation Bio
- InnoCare Pharma Ltd
- Interprotein Corp
- Jazz Pharmaceuticals Plc
- Jiangxi Shanxing Biotechnology Co Ltd
- Johnson & Johnson
- Juventas Cell Therapy Ltd
- Karyopharm Therapeutics Inc
- Kecellitics Biotech Co Ltd
- Kenjockety Biotechnology Inc
- Kiromic BioPharma Inc
- Kronos Bio Inc
- Kymera Therapeutics Inc
- Legend Biotech Corp
- LegoChem Biosciences Inc
- Les Laboratoires Servier SAS
- Light Chain Bioscience
- Lin Bioscience Inc
- Luminary Therapeutics Inc
- MAA Laboratories Inc
- MacroGenics Inc
- Mana Therapeutics Inc
- MannKind Corp
- ManysmarT Therapeutics Inc
- Marker Therapeutics Inc
- medac GmbH
- MediSix Therapeutics Pte Ltd
- MedPacto Inc
- Merck & Co Inc
- Meryx Inc
- Millennium Pharmaceuticals Inc
- Miltenyi Biomedicine GmbH
- Mito BioPharm LLC
- Molecular Templates Inc
- Nabriva Therapeutics Plc
- Nanjing Bioheng Biotech Co Ltd
- Nanjing CART Medical Technology Co Ltd
- Nanjing Iaso Biotherapeutics Co Ltd
- Nanjing KAEDI Biotech Inc
- Nanocopoeia LLC
- NanoValent Pharmaceuticals Inc
- Nektar Therapeutics
- Newave Pharmaceutical Inc
- Nkarta Inc
- Nohla Therapeutics Inc
- Novartis AG
- NovoMedix LLC
- Omeros Corp
- Onconova Therapeutics Inc
- OncoSynergy Inc
- OncoTartis Inc
- OneChain Immunotherapeutics
- Orca Biosystems Inc
- Orgenesis Inc
- Oxcia AB
- Pascal Biosciences Inc
- PentixaPharm GmbH
- PeproMene Bio Inc
- PersonGen BioTherapeutics (Suzhou) Co Ltd
- Pfizer Inc
- Pharma Mar SA
- PharmaEssentia Corp
- Pinotbio Inc
- Porton Biopharma Ltd
- PPD Australia Pty Ltd
- Precigen Inc
- Precision Biosciences Inc
- Provectus Biopharmaceuticals Inc
- PTC Therapeutics Inc
- Regenacy Pharmaceuticals LLC
- Regeneron Pharmaceuticals Inc
- ReguGene Co Ltd
- Retrotherapy LLC
- Ryvu Therapeutics SA
- Sabz Biomedicals
- Sana Biotechnology Inc
- Sanofi
- Sareum Holdings Plc
- SciTech Development LLC
- SELLAS Life Sciences Group Inc
- Shandong New Time Pharmaceutical Co Ltd
- Shanghai Biomed-Union Biotechnology Co Ltd
- Shanghai Bioray Laboratory Inc
- Shanghai GeneChem Co Ltd
- Shanghai Keqi Pharmaceutical Technology Co Ltd
- Shanghai Longyao Biotechnology Co Ltd
- Shanghai Pharmaceuticals Holding Co Ltd
- Shanghai Simnova Biotechnology Co Ltd
- Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
- Shanghai YaKe Biotechnology Co Ltd
- Shenzhen BinDeBio Ltd
- Shorla Pharma Ltd
- SinoCelltech Group Ltd
- Smart Immune SAS
- Sorrento Therapeutics Inc
- SpecificiT Pharma Inc
- Sumitomo Pharma Co Ltd
- Sun Pharma Advanced Research Company Ltd
- Sunnycell Therapeutics Ltd
- SunRock Biopharma SL
- Suzhou Fundamenta Therapeutics Co Ltd
- Synaptogenix Inc
- Syncopation Life Sciences Inc
- Syndax Pharmaceuticals Inc
- SYNIMMUNE GmbH
- Systimmune Inc
- Tacitus Therapeutics Inc
- Takara Bio Inc
- Takeda Pharmaceutical Co Ltd
- TC BioPharm Ltd
- TCR2 Therapeutics Inc
- Telix Pharmaceuticals Ltd
- Tianjin Mycure Medical Technology Co Ltd
- Tianweiyuan and Biomedicine Shanghai Co Ltd
- TotalClarity Inc
- Triphase Accelerator Corp
- TScan Therapeutics Inc
- UWELL Biopharma Inc
- Vincerx Pharma Inc
- VioQuest Pharmaceuticals Inc (Inactive)
- Wellington Zhaotai Therapies Ltd
- Wugen Inc
- Wuhan Bio-Raid Biotechnology Co Ltd
- Wyze Biotech Co Ltd
- Xbrane Biopharma AB
- Xencor Inc
- Xi'An Yufan Biotechnology Co Ltd
- Xiamen Nuokang Biotechnology Co Ltd
- Xspray Pharma AB
- Zhejiang Teruisi Pharmaceutical Co Ltd
- Zhuobo Yong Ji (Shanghai) Biological Pharmaceutical Co Ltd
- Zovis Pharmaceuticals
